Table 2 Clinical features of BCG local adverse reactions.
Injection site abscess | Any BCG dose | First BCG | BCG revaccinated | p value |
|---|---|---|---|---|
n = 41 | n = 10 | n = 31 | ||
Clinical features | ||||
Time to onset, days | 20 (3–45) | 27 (12–45) | 16 (3–41) | 0.008 |
Maximum size, cm | 2 (1.5–5.0) | 2.5 (1.5–5.0) | 2 (1.5–4.5) | 0.12 |
Abscess with discharge | 41 (100%) | 10 (100%) | 31 (100%) | |
Abscess with persistent discharge (>2w) | 24 (59%) | 5 (50%) | 19 (61%) | 0.39 |
Abscess with pain/tenderness at site | 40 (98%) | 10 (100%) | 30 (97%) | |
Management | ||||
Observation | 34 (83%) | 7 (70%) | 27 (87%) | |
Maximum size, cm | 2 (1.5–5.0) | 2 (1.5–5.0) | 2 (1.5–4.0) | |
Time to resolution, days | 27 (2–243) | 28 (8–81) | 22 (2–243) | 0.43 |
Antimicrobial only | 5 (12%) | 2 (20%) | 3 (10%) | |
Topical antibiotic (mupirocin) | 1 | 0 | 1 | |
Maximum size, cm | 2.5 | — | 2.5 | |
Time to resolution, days | 28 | — | 28 | |
Oral antibiotics (cephalexin/flucloxacillin) | 2 | 1 | 1 | |
Maximum size, cm | 3.5 | 5.0 | 2.0 | |
Time to resolution, days | 15 (8–21) | 8 | 21 | |
Oral isoniazid | 2 | 1 | 1 | |
Maximum size, cm | 4.3 (4.0–4.5) | 4.0 | 4.5 | |
Time to resolution, days | 131 | 113 | 149 | |
Fine needle aspiration + cephalexin | 2 (5%) | 1 (10%) | 1 (3%) | |
Maximum size, cm | 2.0 (2.0–2.0) | 2.0 | 2.0 | |
Time to resolution, days | 43 (30–56) | 56 | 30 | |
Lymphadenopathy | Any BCG dose | First BCG | BCG revaccinated | p value |
|---|---|---|---|---|
n = 48 | n = 18 | n = 30 | ||
Clinical features | ||||
Time to onset, days | 6 (1–56) | 6 (1–56) | 6 (1–42) | 0.29 |
Maximum size, cm | 1.8 (0.5–4.0) | 1.8 (0.5–4.0) | 1.5 (0.5–3.0) | 0.46 |
No. (%) with pain/tenderness at site | 30 (63%) | 14 (78%) | 16 (53%) | 0.13 |
Time to resolution, days | 4 (1–30) | 6 (1–30) | 3 (1–14) | 0.47 |
